Amneal Pharmaceuticals(us:AMRX)
7.79
+0.13%
Updated on 2024-12-23
Open:7.78
Close:7.79
High:7.84
Low:7.65
Pre Close:7.78
Volume:338104.00
Amount:2.63M
Turnover:0.11%
Shares:309.84M
MarketCap:2.41B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 203 | 140937584 | 45.54% | 34 | 70 | 69 |
| 2024-03-31 | 177 | 107886322 | 34.96% | 29 | 66 | 52 |
| 2023-12-31 | 176 | 109081685 | 35.58% | 33 | 51 | 70 |
| 2023-09-30 | 157 | 101799761 | 33.22% | 31 | 53 | 47 |
| 2023-06-30 | 154 | 97420362 | 31.82% | 11 | 47 | 66 |
| 2023-03-31 | 159 | 96672065 | 31.65% | 9 | 47 | 62 |
| 2022-12-31 | 184 | 101804590 | 33.53% | 29 | 49 | 75 |
| 2022-09-30 | 180 | 99542534 | 32.79% | 26 | 43 | 77 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Ubs Group Ag | 21849523 | 7.06% | 21671365 | 12164.13% |
| 2024-06-30 | Vanguard Group Inc | 13994178 | 4.52% | 265945 | 1.94% |
| 2024-06-30 | Tpg Gp A, Llc | 12328767 | 3.98% | 0 | |
| 2024-06-30 | Blackrock Inc. | 11282430 | 3.65% | 2118258 | 23.11% |
| 2024-06-30 | Rubric Capital Management Lp | 10721778 | 3.46% | 1179830 | 12.37% |
| 2024-06-30 | Citadel Advisors Llc | 9988725 | 3.23% | 4921242 | 97.11% |
| 2024-06-30 | Nantahala Capital Management, Llc | 5339886 | 1.73% | 2719943 | 103.82% |
| 2024-06-30 | Fosun International Ltd | 4655403 | 1.50% | -7658845 | -62.20% |
| 2024-06-30 | Dimensional Fund Advisors Lp | 4283928 | 1.38% | 641405 | 17.61% |
| 2024-06-30 | Neuberger Berman Group Llc | 3568353 | 1.15% | -352622 | -8.99% |
About
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.
Address:400 Crossing Boulevard,3rd floor
Website:http://www.amneal.com
Market Movers